First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04528836. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT04528836
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Navire Pharma Inc., a BridgeBio company
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- BBP-398 (Formerly known as IACS-15509) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 11, 2020
- Primary completion
- Mar 21, 2024
- Completion
- Jul 29, 2024
- Last update posted
- Dec 11, 2024
2020 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| City of Hope | Duarte | California | 91010 | — |
| Scripps MD Anderson Cancer Center | La Jolla | California | 92037 | — |
| UC Irvine Health | Orange | California | 92868 | — |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | — |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77096 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| NEXT Virginia | Fairfax | Virginia | 22031 | — |
| MultiCare Institute for Research & Innovation | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04528836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 11, 2024 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04528836 live on ClinicalTrials.gov.